Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

丙卡巴嗪 替莫唑胺 医学 洛莫司汀 内科学 肿瘤科 少突胶质瘤 长春新碱 无进展生存期 达卡巴嗪 化疗 放射治疗 胶质瘤 癌症研究 环磷酰胺 星形细胞瘤
作者
Salah Eddine Oussama Kacimi,Caroline Dehais,L. Feuvret,Olivier Chinot,Alain Carpentier,Charlotte Bronnimann,Élodie Vauléon,Apolline Djelad,Elizabeth Cohen‐Jonathan Moyal,Olivier Langlois,Mario Campone,Mathilde Ducloie,G. Noël,Stefania Cuzzubbo,Luc Taillandier,Carole Ramirez,Nadia Younan,Philippe Meneï,F. Dhermain,C. Desenclos,François Ghiringhelli,Veronique Bourg,Damien Ricard,Thierry Faillot,Romain Appay,Émeline Tabouret,Lucia Nichelli,Bertrand Mathon,Alice Thomas,Suzanne Tran,Franck Bielle,Agustí Alentorn,J. Bryan Iorgulescu,Pierre‐Yves Boëlle,Karim Labreche,Khê Hoang‐Xuan,Marc Sanson,Ahmed Idbaïh,Dominique Figarella‐Branger,François Ducray,Mehdi Touat,C. Desenclos,N. Guillain,Philippe Meneï,Audrey Rousseau,T Cruel,Saioa López,M. Abad,N. Hamdan,Clovis Adam,Fabrice Parker,Romuald Seizeur,Isabelle Quintin‐Roué,Guillaume Chotard,Charlotte Bronnimann,Damien Ricard,Catherine Godfraind,Toufik Khallil,Dominique Cazals‐Hatem,Thierry Faillot,C. Gaultier,M.-C. Tortel,Ioana Carpiuc,Philippe Richard,H. Aubriot-Lorton,François Ghiringhelli,Apolline Djelad,Claude‐Alain Maurage,E.M. Gueye,François Labrousse,François Ducray,David Meyronet,Dominique Figarella‐Branger,Olivier Chinot,Luc Bauchet,Valérie Rigau,G. Gauchotte,Luc Taillandier,Mario Campone,Delphine Loussouarn,Veronique Bourg,F. Vandenbos-Burel,Jean Sébastien Guillamo,Pascal Roger,Claire Bléchet,H. Adle-Biassette,Franck Bielle,Alain Carpentier,Caroline Dehais,Serge Milin,Michel Wager,Philippe Colin,M.D. Diebold,Danchristian Chiforeanu,Élodie Vauléon,Florent Marguet,Olivier Langlois,Fabien Forest,M.J. Motso-Fotso,Marie Andraud,Benoît Lhermitte,G. Noël,Michèle Bernier,Nadia Younan,Cécilia Rousselot-Denis,Ilyess Zemmoura,Christophe Joubert,Elisabeth Cohen-Moyal,Emmanuelle Uro‐Coste,F. Dhermain
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
标识
DOI:10.1200/jco.24.00049
摘要

PURPOSE Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3 IDHmt/Codel ) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV) and temozolomide (TMZ) remains unclear given the lack of randomized trial data comparing both regimens. METHODS The objective was to assess the overall survival (OS) and progression-free survival (PFS) associated with first-line PCV/RT versus TMZ/RT in patients newly diagnosed with O3 IDHmt/Codel . We included patients with histologically proven O3 IDHmt/Codel (according to WHO criteria) from the French national prospective cohort Prise en charge des OLigodendrogliomes Anaplasiques (POLA). All tumors underwent central pathological review. OS and PFS from surgery were estimated using the Kaplan-Meier method and Cox regression model. RESULTS 305 newly diagnosed patients with O3 IDHmt/Codel treated with RT and chemotherapy between 2008 and 2022 were included, of which 67.9% of patients (n = 207) were treated with PCV/RT and 32.1% with TMZ/RT (n = 98). The median follow-up was 78.4 months (IQR, 44.3-102.7). The median OS was not reached (95% CI, Not reached [NR] to NR) in the PCV/RT group and was 140 months (95% CI, 110 to NR) in the TMZ/RT group (log-rank P = .0033). On univariable analysis, there was a significant difference in favor of PCV/RT in both 5-year (PCV/RT: 89%, 95% CI, 85 to 94; TMZ/RT: 75%, 95% CI, 66 to 84) and 10-year OS (PCV/RT: 72%, 95% CI, 61 to 85; TMZ/RT: 60%, 95% CI, 49 to 73), which was confirmed using the multivariable Cox model adjusted for age, type of surgery, gender, Eastern Cooperative Oncology Group performance status, and CDKN2A homozygous deletion (hazard ratio, 0.53 for PCV/RT, 95% CI, 0.30 to 0.92, P = .025). CONCLUSION In patients with newly diagnosed O3 IDHmt/Codel from the POLA cohort, first-line PCV/RT was associated with better OS outcomes compared with TMZ/RT. Our data suggest that the improved safety profile associated with TMZ comes at the cost of inferior efficacy in this population. Further investigation using prospective randomized studies is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zz123完成签到,获得积分10
1秒前
1秒前
呵呵喊我完成签到,获得积分10
1秒前
2秒前
sd发布了新的文献求助10
2秒前
2秒前
hxxx发布了新的文献求助10
3秒前
3秒前
Stove发布了新的文献求助10
3秒前
绿色催化完成签到,获得积分10
4秒前
4秒前
濑濑发布了新的文献求助10
4秒前
安安完成签到,获得积分10
5秒前
白兰鸽完成签到,获得积分10
5秒前
terryok发布了新的文献求助10
5秒前
喻踏歌完成签到,获得积分10
6秒前
DIVA完成签到,获得积分10
7秒前
8秒前
8秒前
康康星发布了新的文献求助20
8秒前
xytyyy发布了新的文献求助10
9秒前
9秒前
HanQing发布了新的文献求助10
9秒前
ZYC007发布了新的文献求助10
10秒前
单薄的书琴完成签到,获得积分20
11秒前
11秒前
11秒前
不懈奋进应助happy_jadeyu采纳,获得30
11秒前
dan完成签到,获得积分10
12秒前
12秒前
hxxx完成签到,获得积分10
12秒前
何小龙关注了科研通微信公众号
12秒前
2810527600发布了新的文献求助10
13秒前
TGR发布了新的文献求助10
14秒前
14秒前
123发布了新的文献求助10
15秒前
77发布了新的文献求助10
15秒前
15秒前
15秒前
脑洞疼应助MR_Z采纳,获得10
16秒前
高分求助中
Sustainability in Tides Chemistry 2000
The ACS Guide to Scholarly Communication 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Ожившие листья и блуждающие цветы. Практическое руководство по содержанию богомолов [Alive leaves and wandering flowers. A practical guide for keeping praying mantises] 500
A Dissection Guide & Atlas to the Rabbit 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3079871
求助须知:如何正确求助?哪些是违规求助? 2732588
关于积分的说明 7524713
捐赠科研通 2381420
什么是DOI,文献DOI怎么找? 1262876
科研通“疑难数据库(出版商)”最低求助积分说明 612123
版权声明 597460